Di Micco, P.; Salazar, V.R.; Capitan, C.F.; Dentali, F.; Cuervo, C.G.; Reyes, J.L.F.; Porras, J.A.; Fidalgo, A.; Grandone, E.; Meseguer, M.L.;
et al. Rivaroxaban Monotherapy in Patients with Pulmonary Embolism: Off-Label vs. Labeled Therapy. Life 2022, 12, 1128.
https://doi.org/10.3390/life12081128
AMA Style
Di Micco P, Salazar VR, Capitan CF, Dentali F, Cuervo CG, Reyes JLF, Porras JA, Fidalgo A, Grandone E, Meseguer ML,
et al. Rivaroxaban Monotherapy in Patients with Pulmonary Embolism: Off-Label vs. Labeled Therapy. Life. 2022; 12(8):1128.
https://doi.org/10.3390/life12081128
Chicago/Turabian Style
Di Micco, Pierpaolo, Vladimir Rosa Salazar, Carmen Fernandez Capitan, Francesco Dentali, Covadonga Gomez Cuervo, José Luis Fernández Reyes, Jose Antonio Porras, Angeles Fidalgo, Elvira Grandone, Manuel Lopez Meseguer,
and et al. 2022. "Rivaroxaban Monotherapy in Patients with Pulmonary Embolism: Off-Label vs. Labeled Therapy" Life 12, no. 8: 1128.
https://doi.org/10.3390/life12081128
APA Style
Di Micco, P., Salazar, V. R., Capitan, C. F., Dentali, F., Cuervo, C. G., Reyes, J. L. F., Porras, J. A., Fidalgo, A., Grandone, E., Meseguer, M. L., Monreal, M., & the RIETE Investigators.
(2022). Rivaroxaban Monotherapy in Patients with Pulmonary Embolism: Off-Label vs. Labeled Therapy. Life, 12(8), 1128.
https://doi.org/10.3390/life12081128